HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 91.6%

Neg 91.6% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.